Aleksandra Malcher

Aleksandra Malcher

Auto-generated profile, based on publicly available information

Aleksandra Malcher

Nicolaus Copernicus Hospital in Gdańsk, Nowe Ogrody 1-6, 80-803, Gdańsk, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2026 in Quality in Sport
Verified
Journal Article
Open access
IZIgor Zydlewski
Igor Zydlewski
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
MMMartyna Mrozek
Martyna Mrozek
MPMartyna Pacanowska-Trawnicka
Martyna Pacanowska-Trawnicka
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
AMAleksandra Malcher
Aleksandra Malcher
Introduction Aortic stenosis is the most common acquired, valvular heart disease among adults in developed countries. It causes exercise tolerance deterioration, left ventricle hypertrophy and leads to heart failure or even death. Available treatment methods for severe, symptomatic aortic stenosis include Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement (SAVR). While it has been proven that TAVI is superior to SAVR in patients with high surgical risk, there is still little data considering patients with lower risk profile. Aim of study The aim of this study is to assess the differences between TAVI procedure and the Surgical Aortic Valve Replacement in terms of their efficacy and safety in patients with severe aortic stenosis and low to intermediate surgical risk. This article is based on the analysis of randomised controlled trials published between years 2021 and 2026. Conclusion TAVI is a safe and effective alternative to SAVR in patients with severe, symptomatic aortic stenosis and low to intermediate surgical risk. It is associated with a lower incidence of major bleeding, stroke and myocardial infarction while presenting comparable or lower mortality in short to medium term. It is, however, correlated with more frequent vascular complications and pacemaker implantations. There is a need for further research on a larger group of patients, with a longer follow-up time in order to assess optimal guidelines for TAVI and SAVR in patients with this risk profile.

16 April 2026 in Quality in Sport
Verified
Journal Article
Open access
PDF file
MPMartyna Pacanowska-Trawnicka
Martyna Pacanowska-Trawnicka
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
IZIgor Zydlewski
Igor Zydlewski
MMMartyna Mrozek
Martyna Mrozek
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
AMAleksandra Malcher
Aleksandra Malcher
Introduction: Caffeine is a methylxanthine compound naturally found in coffee beans, tea leaves, and cocoa. It is among the most widely consumed psychoactive substances worldwide. Its primary mechanism of action involves antagonism of adenosine receptors within the central nervous system, resulting in reduced perception of fatigue and enhanced alertness. Caffeine’s effects on the peripheral nervous system include increased intracellular calcium release and inhibition of phosphodiesterase activity, thereby enhancing muscle contractility and promoting utilization of energy substrates [1]. The metabolic effects of caffeine encompass multiple biochemical pathways [8]. Although caffeine exerts a multifactorial effect on aerobic performance its use should be carefully considered in the context of potential adverse effects [12]. Evidence derived from studies conducted in diverse athletic populations suggests that caffeine supplementation may represent an effective strategy for optimizing performance while preserving long-term athlete health.Aim of the study :The aim of this study is to systematically analyze available literature regarding the effects of caffeine, its mechanisms of action, safety profile, adverse effects, and variability in response according to sport discipline and sex.Material and Methods: Review and analysis of randomized clinical trials and clinical trials from 2010 to 2025 available on PubMed and Google Scholar.Conclusions: The findings indicate that caffeine may serve as an effective ergogenic aid across a wide range of sports disciplines, provided that it is administered within safe dosage ranges tailored to individual needs—taking into account the specific characteristics of the discipline, athlete-related factors and individual tolerance [2]. Furthermore, current evidence indicates comparable magnitude of benefits in both female and male athletes across various disciplines [5], highlighting the broad applicability of caffeine as an ergogenic aid.

30 May 2026 in Quality in Sport
Verified
Journal Article
Open access
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AMAleksandra Malcher
Aleksandra Malcher
MMMartyna Mrozek
Martyna Mrozek
IZIgor Zydlewski
Igor Zydlewski
Introduction: Facing the increasing number of people suffering from obesity, overweight and weight-related comorbidities, the development of medications that support weight loss is crucial. The currently available therapies based on glucagon-like peptide receptor 1 agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide/GLP-1 RAs allow for weight loss of 8-21% [1]. However, a significant factor reducing treatment adherence is subcutaneous route of administation by injection, as well ass - in the case of oral semaglutide – restrictive dosing requirements: the drug need to be taken at least 30 minutes before the first meal, beverage, or other oral medication in the morning and with no more than 120 ml of plain water [2]. Aim of the study: The purpose of this study is to review the safety and tolerance of orforglipron and to compare it with oral semaglutide based on ACHIEVE-3 clinical trail. Material and Methods: Review and analysis of randomised clinical trials available on PubMed. We excluded phase 1 trials in analysis of patients with obesity without diabetes mellitus and patients with DM2. Notably, main clinical trials focusing on orforglipron were funded or supported by Eli Lilly and Company. Conclusions: Orforglipron is definitely promising as a small-molecule GLP-1 receptor agonist. The therapy is effective in body weight reduction and results in a significant, dose-dependent reduction in HbA1c levels. With significant effect on weight loss, cardiometabolic parameters and improvement in glycemic profile, it can be used in combination with a reduced-calorie diet and increased physical activity in adults, as a weight-loss therapy or in patient with type 2 diabetes. However, all of the studies published so far on the innovative molecule of orforglipron were based on limited number of patients, therefore long-term safety, tolerance in a larger population and general long-term impact of orforglipron on health needs extensive studies.

16 May 2026 in Quality in Sport
Verified
Journal Article
Open access
AZAgnieszka Zielińska
Agnieszka Zielińska
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
MMMartyna Mrozek
Martyna Mrozek
IZIgor Zydlewski
Igor Zydlewski
AMAleksandra Malcher
Aleksandra Malcher
Background. Congenital heart diseases (CHDs) are the most common congenital anomalies and a leading cause of infant morbidity and mortality. Although genetic factors play an important role, many cases remain unexplained, highlighting the contribution of maternal and environmental exposures. Aim. This review aims to provide a comprehensive and up-to-date synthesis of non-genetic maternal risk factors associated with CHDs in offspring. Material and methods. A literature review was conducted using PubMed, NCBI and Google Scholar, including studies published between 2010 and 2025. Systematic reviews, meta-analyses, cohort and case-control studies evaluating maternal and environmental exposures were analyzed. Results. Evidence indicates that maternal diabetes and obesity are key risk factors, with clear dose-response relationships. Additional contributors include smoking (active and passive), alcohol consumption, infections, fever, psychological stress and environmental pollutants. Protective effects of folic acid and multivitamin supplementation were also observed. Interaction effects between environmental exposures and parental behaviors further increase CHD risk. Conclusions. CHD etiology is multifactorial, involving modifiable maternal and environmental factors. Identification and reduction of these exposures, particularly during early pregnancy, are essential for prevention. Further prospective and mechanistic studies are needed to clarify causal pathways and improve risk reduction strategies.

30 May 2026 in Quality in Sport
Verified
Journal Article
Open access
AMAleksandra Malcher
Aleksandra Malcher
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AZAgnieszka Zielińska
Agnieszka Zielińska
IZIgor Zydlewski
Igor Zydlewski
AJAleksandra Jakimowicz
Aleksandra Jakimowicz
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
Background. Women's participation in sport has grown substantially, yet female athletes remain underrepresented in sport science research, with much of the existing evidence derived from male populations. Fluctuations of estrogen and progesterone across the menstrual cycle, together with widespread use of hormonal contraceptives, are increasingly recognised as factors that may influence athletic outcomes. Aim. To synthesise current evidence on the effects of female reproductive hormones on athletic performance, injury risk, and recovery, and to translate it into practical, individualised recommendations for coaches, practitioners, and athletes. Methods. PubMed was searched for systematic reviews, meta-analyses, and original studies on the menstrual cycle, hormonal contraceptives, and athletic outcomes. Results. Group-level effects of menstrual cycle phase on objective performance outcomes such as strength, power, and endurance are generally small and inconsistent. Evidence linking cycle phase to anterior cruciate ligament injury risk is suggestive but limited by methodological heterogeneity, whereas hormonal contraceptive use does not appear to be protective against musculoskeletal injuries. Outcomes related to recovery appear more sensitive to hormonal context than objective performance measures, with recent evidence converging on menstrual symptom burden as a predictor of disturbed recovery in female athletes. Conclusions. Female reproductive hormones influence multiple physiological systems relevant to sport, but their effects on athletic outcomes are predominantly individual rather than uniform. The strongest evidence-based approach for supporting female athletes combines individualised, symptom-led monitoring with established principles of training periodisation, injury prevention, and athlete education. Progress in this field will depend on longitudinal research with biochemical phase verification and a focus on individual response patterns.

7 May 2026 in Journal of Education, Health and Sport
Verified
Journal Article
Open access
MMMartyna Mrozek
Martyna Mrozek
MBMałgorzata Blecharczyk
Małgorzata Blecharczyk
ZKZuzanna Zofia Kamińska
Zuzanna Zofia Kamińska
AZAgnieszka Zielińska
Agnieszka Zielińska
IZIgor Zydlewski
Igor Zydlewski
AMAleksandra Malcher
Aleksandra Malcher
PROM and its preterm form, pPROM, are major contributors to preterm birth and remain closely associated with serious maternal and neonatal complications. Growing evidence suggests that disruption of vaginal microbial homeostasis mayis closely linked to the pathogenesis of pPROM. In particular, the loss of protective Lactobacillus crispatus, accompanied by a shift toward Lactobacillus iners, anaerobic bacteria, and increased microbial diversity, appears to destabilize the vaginal ecosystem, promote local inflammation, activate matrix metalloproteinases, and ultimately compromise the structural integrity of the fetal membranes. Current empirical antibiotic therapy for pPROM does not account for interindividual variability in the vaginal microbiota and may paradoxically aggravate dysbiosis. In response to these limitations, emerging therapeutic strategies are increasingly focused on microbiota-targeted interventions, including personalized probiotic therapies, immunological and biological approaches, and vaginal microbiota transplantation. In addition, specific microbial signatures may serve as potential biomarkers of pPROM, thereby opening new avenues for personalized prevention and treatment. Although further prospective studies are required to validate the safety and efficacy of these emerging therapies, their potential already represents a promising direction for the future of modern perinatal medicine.